Who Supplies Plasma to India from ALGERIA

To import finished pharmaceutical formulations containing plasma into India, the foreign manufacturer must obtain an Import License from the Directorate General of Foreign Trade (DGFT). The importer in India must register the product with the Central Drugs Standard Control Organisation (CDSCO) by submitting Form 40 or 41, depending on the product's classification. The registration process includes providing a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for import drug registration varies but typically ranges from several months to a year, depending on the complexity of the product and the completeness of the submitted documentation. For formulations under HS Code 30029010, specific requirements include detailed product information, manufacturing details, and compliance with Indian pharmacopoeia standards.

Imported finished pharmaceutical formulations containing plasma must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported products. Failure to meet these requirements can result in delays, rejections, or destruction of the consignment.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. Bilateral agreements with Algeria have been explored to facilitate smoother trade relations, including mutual recognition of GMP standards and streamlined import procedures. These developments aim to balance the promotion of domestic industry with the need for high-quality imported formulations.

India imports finished pharmaceutical formulations containing plasma to meet the demand for specialized treatments not fully addressed by domestic production. This includes patented or branded formulations, specific dosage forms, and products requiring advanced manufacturing technologies. The market size for such imports is significant, with India's total plasma formulation export market valued at $2.8 million across 215 exporters to 90 countries. The reliance on imports is due to the limited domestic capacity to produce certain complex plasma-based formulations.

The Basic Customs Duty for HS Code 30029010 is 10%. An additional 3% Education Cess is applied, totaling 10.3%. The Integrated Goods and Services Tax (IGST) is 0% for this category. There are no additional duties such as Anti-Dumping Duty or National Calamity Contingent Duty (NCCD) applicable. Exemption notifications may apply under specific trade agreements or for products meeting certain criteria. The total landed duty percentage is 10.3%.

India sources finished pharmaceutical formulations containing plasma from Algeria due to Algeria's competitive advantages, including the availability of patented formulations, specialized dosage forms, and high-quality manufacturing practices. Algeria's share in India's plasma formulation imports is notable, though specific figures are not disclosed. Other suppliers include China, Germany, and the United States, each offering different advantages in terms of price, quality, and regulatory compliance.

India imports finished pharmaceutical formulations containing plasma from Algeria due to Algeria's ability to supply patented formulations, specialized dosage forms, and products manufactured under stringent quality controls. These products may not be available domestically, necessitating imports to meet patient needs.

Compared to other origins like China, the European Union, and the United States, Algeria offers competitive pricing and high-quality products. Algeria's regulatory compliance and reliability in supply chains make it an attractive source for India.

Potential risks include single-source dependency, currency fluctuations, regulatory changes in Algeria, quality incidents, and shipping disruptions. Past shortages have been minimal, but importers should maintain contingency plans.

1. 1Dual-Sourcing: Engage multiple suppliers to mitigate risks associated with single-source dependency.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against potential supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP) to manage financial risks.
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to optimize inventory and reduce costs.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers to ensure compliance with quality and regulatory standards.

1. 1DGFT Import License: Obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Submit Form 40 or 41 to CDSCO, along with required documents.
3. 3Drug Import License: Apply for a license under the Drugs and Cosmetics Act, 1940.
4. 4No Objection Certificate (NOC): If applicable, obtain NOC from the Ministry of Health and Family Welfare.
5. 5Customs Broker: Engage a licensed customs house agent for clearance procedures.
6. 6Advance Ruling: Seek advance ruling for HS Code 30029010 to confirm classification and applicable duties.

1. 1Certificate of Analysis (CoA): Confirming product quality and compliance.
2. 2Certificate of Pharmaceutical Product (CoPP): Indicating regulatory approval in Algeria.
3. 3Good Manufacturing Practice (GMP) Certificate: Demonstrating adherence to quality standards.
4. 4Drug Master